Perioprative Outcomes for Children With URTI Symptoms
Launched by AIJUN XU ·
Trial Information
Current as of November 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is an observational look at whether having mild upper respiratory tract infection (URTI) symptoms in the two weeks before elective non-heart surgery affects how children recover. Researchers will review past records from Tongji Hospital in Wuhan, China, comparing children who had URTI symptoms (symptom group) with those who did not (control group). The project plans to include about 2,392 children aged 1 to 12 years who had non-cardiac surgery between 2015 and 2024. This is a retrospective study, meaning researchers are analyzing existing data rather than enrolling new patients. Results are not yet available, and the study is currently not recruiting, with estimated start in September 2025 and finishing by late October 2025.
To be eligible, children should be 1 to 12 years old, have an ASA health score of I–III, and be undergoing elective non-cardiac surgery. Those with severe illnesses (like serious heart problems or immune issues), a single fever due to another cause, or day-surgery procedures are excluded. The main thing the study will look at is whether URTI symptoms are linked to more problems after surgery within 7 days, including bleeding, infection, stomach or bowel issues, respiratory problems, or a return of the original disease. They will also track breathing problems during or right after surgery, and how long kids spend in recovery or in the hospital.
Gender
ALL
Eligibility criteria
About Aijun Xu
Aijun Xu is a clinical trial sponsor who provides leadership and oversight for the planning, initiation, and conduct of clinical studies. In this role they ensure regulatory compliance, participant safety, and data integrity by coordinating protocol development, quality assurance, and study governance. They work closely with investigators, contract research organizations, ethics committees, and regulatory authorities to manage timelines, budgets, and reporting obligations. Aijun Xu is committed to advancing rigorous, ethically conducted research that translates into reliable clinical evidence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
aihua Du, Dr.
Study Chair
Tongji Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported